Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trial supports wider use of Vernalis and Endo’s migraine drug
Endo expects to file a supplemental new drug application with the FDA in the coming weeks to seek approval for the expanded indication. Frova is currently approved for
Endo expects to file a supplemental new drug application with the FDA in the coming weeks to seek approval for the expanded indication. Frova is currently approved for
Paliperidone, which releases drug into the bloodstream steadily over a 24-hour period, is an extended release version of Johnson & Johnson’s blockbuster schizophrenia treatment Risperdal. The paliperidone filing
Under the deal, Kos will have exclusive rights to market Flutiform in the US and a right of first negotiation in Canada. SkyePharma has received an upfront payment
The combined company, now called Micromet Inc, is headquartered in Delaware in the US with Micromet AG becoming a wholly-owned subsidiary of the merged company. Under the terms
DeCode now plans to use the discovery of the variation in chromosome 8 to develop a diagnostic test to improve screening for the disease. According to the researchers,
The product, polyethylene glycol 3350 NF for oral solution, is the AB-rated generic equivalent of Braintree’s Miralax for oral solution. According to Teva, total annual sales of the
The study showed a statistically significant reduction in the number and severity of moderate and severe hot flashes for all three doses tested. The most effective Evamist dose
GlaxoSmithKline was awarded $274.75 million, MedImmune is to receive $169.46 million, Novartis won $220.51 million, DynPort was awarded $40.97 million, and Solvay Pharmaceuticals is to receive $298.59 million.
This multi-national study was successfully initiated outside the US in 2005, and will now expand to include 17 clinical trial sites in the US. The study is one
After evaluating data from analysis recently obtained results from the first four of eight phase III clinical trials and one phase II trial, the company decided that the